Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens.

[1]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  T. Fukuda,et al.  Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis , 2013, Intensive Care Medicine.

[3]  Tetsuya Matsumoto,et al.  Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[4]  Brian S. Smith,et al.  Introduction to drug pharmacokinetics in the critically ill patient. , 2012, Chest.

[5]  K. Yanagihara,et al.  The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  F. Pea,et al.  TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient , 2011, The Annals of pharmacotherapy.

[7]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[8]  K. Matsuyama,et al.  Factors Influencing Peak Concentrations of Arbekacin in Patients , 2009 .

[9]  R. Maziarz,et al.  Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever , 2008, Antimicrobial Agents and Chemotherapy.

[10]  Y. Tanigawara,et al.  Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[11]  Y. Tanigawara,et al.  Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[12]  P. Viale,et al.  Antimicrobial Therapy in Critically Ill Patients , 2005, Clinical pharmacokinetics.

[13]  R. Arbeit,et al.  Population Pharmacokinetics of Daptomycin , 2004, Antimicrobial Agents and Chemotherapy.

[14]  M. Barclay,et al.  The therapeutic monitoring of antimicrobial agents. , 2001, British journal of clinical pharmacology.

[15]  E. Ette,et al.  Stability and Performance of a Population Pharmacokinetic Model , 1997, Journal of clinical pharmacology.

[16]  A. Nafziger,et al.  Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing , 1997, Antimicrobial agents and chemotherapy.

[17]  J. Ioannidis,et al.  Single or multiple daily doses of aminoglycosides: a meta- analysis , 1996, BMJ.

[18]  R. Cipolle,et al.  Kinetic model for gentamicin dosing with the use of individual patient parameters , 1977, Clinical pharmacology and therapeutics.

[19]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[20]  H. Umezawa,et al.  Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria. , 1973, The Journal of antibiotics.